You are here

Discovery of Anti-Bioweapon Agents in BAC Libraries

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41AI056791-01A1
Agency Tracking Number: AI056791
Amount: $488,524.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Solicitation Year: N/A
Award Year: 2004
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
United States
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (608) 347-9192
Business Contact
Phone: (608) 358-5451
Research Institution
4th Floor AW Peterson
Madison, WI 53706
United States

 Nonprofit college or university

DESCRIPTION (provided by applicant): Antibiotics are an essential component in bio-defense preparedness. Soil microorganisms were a major source of antibiotics during the 20th century, yet antibiotic discovery is now severely limited. A primary reason is that drug discovery from microorganisms has been confined to those microbes that can be recovered by laboratory cultivation, yielding high rates of antibiotic rediscovery.

eMetagen's pioneering technology for the direct cloning of microbial genomic DNA from soils will be used to discover new antibiotics targeting NIAID category A and B bio-defense pathogens. Antibiotic biosynthesis pathways typically contain many genes therefore eMetagen's technology for cloning large DNA fragments is critical for antibiotic discovery. Innovative approaches will be used for the construction of large-genomic-DNA-insert libraries (Aim 1) that will be screened in an array format for genes encoding new polyketide antibiotics (Aim 2). eMetagen libraries will also be screened for new classes of broad spectrum antibiotics with activity against bioweapon surrogates (Aim 3).

Intellectual property will include the improved eMetagen libraries, the arrayed libraries, the chemical structures of discovered antibiotics and the genes encoding their synthesis. In Phase II, eMetagen will fully characterize polyketide and other antibiotics discovered in Phase I and partner with pharmaceutical companies and government laboratories to advance product development.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government